Daphnegiravone D

Daphnegiravone D (compound 70) is an HDAC6 inhibitor with anti-hepatocellular carcinoma activity. Daphnegiravone D can induce apoptosis and selectively inhibit the proliferation of liver cancer cells through the p38 and JNK MAPK pathways[1].

Product Specifications

CAS Number

[2581826-37-9]

UNSPSC

12352005

Target

Apoptosis; HDAC; p38 MAPK

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

CANCER

Assay Protocol

https://www.medchemexpress.com/daphnegiravone-d.html

Smiles

O=C1C(OC)=C(C2=CC(C/C=C(C)\C)=C(O)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C31

Molecular Formula

C26H28O6

Molecular Weight

436.50

References & Citations

[1]Wang D, et al. A new Prenylated Flavonoid induces G0/G1 arrest and apoptosis through p38/JNK MAPK pathways in Human Hepatocellular Carcinoma cells. Sci Rep. 2017 Jul 18;7 (1) :5736.|[2]Chen JJ, et al. Network pharmacology predicted HDAC6 as a potential target of flavones from Daphne giraldii on hepatocellular carcinoma. Nat Prod Res. 2021 Sep;35 (18) :3171-3175.